Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Inflamm Intest Dis · 2026 · PMC12782621 · PMID 41523318

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Colectomy: there was a nonsignificant trend toward fewer colectomies in the upadacitinib cohort at the end of study follow-up (OR 0.70; 95% CI: 0.39–1.28; I 2 = 0%) [6 studies; 1,071 patients] ( Fig. 4 d) [ 16 , 17 , 22 – 25 ]. h.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.